Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Trimi vs Royal Medical Center

Two GLP-1 desks, one scoreboard. We put Trimi and Royal Medical Center head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 2 · Grade B+

Trimi

Visit Trimi Full brief →
vs
No. 403 · Grade C

Royal Medical Center

Visit Royal Medical Center Full brief →

The verdict

Trimi takes this head-to-head.

Trimi scores 89 to 55 on our six-factor Brief Score — A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.

That doesn't make Royal Medical Center a bad call — it's best for readers who want credentialed md founder with itemized dose-strength pricing. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
48
Supply Reliability
89
57
Transparency
91
72
Access Breadth
89
40
Clinical Oversight
88
62
Track Record
84
47
TrimiBrief Score 89 · 55Royal Medical Center

Price, coverage & the tracker

TrimiRoyal Medical Center
Brief Score89/100 (B+)55/100 (C)
Semaglutide$196/moNot disclosed
Tirzepatide$296/moFrom $450/mo (2.5 mg dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Trimi: Membership rate held flat this cycle — both molecules disclosed up front, no first-month teaser.

Royal Medical Center: New to the tracker on 1 August 2026. The published line reads From $450/mo (2.5 mg dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.